Randomized trials support the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer based on a noted survival advantage, which appeared to be strongly related to downstaging of the cancer to pT0 (complete pathologic response). This report presents a case of an unusual mast cell response along with bladder wall thickening after neoadjuvant chemotherapy. However, the final cystectomy specimen did not reveal any residual tumor (pT0). The authors hypothesize that neoadjuvant chemotherapy could have caused the diffuse mast cell response, and that this profound inflammatory response can be used as a biomarker of complete response to chemotherapy. (JNCCN 2013;11:1459-1463 
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Learning Objectives
Upon completion of this activity, participants will be able to:
• Describe several treatment options for urinary bladder cancer • Summarize possible pathologic responses to cisplatin-based neoadjuvant therapy
From the a 20% on day 8 of cycle 1 because of thrombocytopenia. At the end of the second cycle of chemotherapy, the patient again developed significant hematuria, dysuria, and increased urinary frequency. An ultrasonogram of the bladder showed diffuse thickening of the bladder wall in addition to the tumor ( Figure 2 ). She was deemed to have progressive disease based on worsening symptoms and bladder wall thickening on ultrasound, with suspected intramural spread. Repeat CT scan of the abdomen and pelvis with contrast showed a decrease in tumor size to 3 x 1 cm along with bladder wall thickening ( Figure 3 ). This was highly suspicious of disease progression. Therefore, chemotherapy was discontinued and she underwent a robot-assisted radical cystectomy with open construction of an ileal neobladder and an extended bilateral pelvic lymph node dissection. 1 Urothelial (transitional cell) carcinomas are the most common histologic subtype in the United States. Cisplatin-based neoadjuvant chemotherapy has been shown to improve survival in patients with localized muscle-invasive bladder cancer. [2] [3] [4] [5] In the metastatic setting, gemcitabine/cisplatin (GC) showed similar efficacy to MVAC (methotrexate/ vinblastine/doxorubicin/cisplatin) in terms of objective response rate, progression-free survival, and overall survival, and had a more favorable toxicity profile. 6 Furthermore, in many studies the rate of downstaging with GC use was comparable to that of MVAC. [7] [8] [9] The GC data in the metastatic setting are extrapolated to the neoadjuvant setting, because they show comparable results with a reduced toxicity profile. Approximately 38% of patients receiving neoadjuvant chemotherapy show a complete pathologic response (pT0) at cystectomy, 4 and the remaining patients have either residual disease or progressive disease. This report presents a case of unusual mast cell response to neoadjuvant chemotherapy, suspicious for disease progression on imaging studies.
Case Report
A 51-year-old woman presented with a 3-week history of gross hematuria and dysuria. She was initially treated with antibiotics for a possible urinary tract infection. However, hematuria persisted and a subsequent CT scan of her abdomen and pelvis (with and without contrast) showed an irregular necroticappearing mass at the bladder dome measuring 5 x 3 cm (Figure 1) . No evidence was seen of lymphadenopathy or metastasis. Cystoscopy confirmed the presence of a mass and she underwent transurethral resection (TUR) of the bladder tumor. After resection, the tumor base was cauterized and a mitomycin cocktail was left indwelling. Hematuria subsided with TUR.
Based on pathology report, patient was started on neoadjuvant chemotherapy with a GC-based regimen for an intended 3 cycles before the planned cystectomy. The dose of gemcitabine was reduced by 
Pathology
The original TUR specimen showed a "high-grade urothelial carcinoma invading into muscularis propria with focal lymphovascular invasion" ( Figure  4 ). Gross inspection of the subsequent cystectomy specimen ( Figure 5 ) showed a firm, orange-tan indurated lesion measuring 1.2 x 0.9 cm located in the posterior aspect of the bladder dome. Microscopic examination revealed an ulcerated granulomatous inflammation, microcalcifications, and fibrosis extending into the muscularis propria, consistent with previous therapy effect ( Figure 6 ). No residual carcinoma was identified (pT0). Interestingly, the muscularis propria showed diffuse mast cells infiltration, up to 33 cells per 1 high-power field (Figure 7 ), which was confirmed by the CD117 immunohistochemical stain (Figure 8) . A total of 24 pelvic lymph nodes were also found to be negative for metastasis.
Discussion
This patient was started on neoadjuvant chemotherapy with GC and developed the symptoms of dysuria, urgency, and frequency. In the context of a thickened bladder wall, this development was concerning for disease progression, and the surgery was appropriately preponed. To the authors' surprise, final pathology results of the cystectomy specimen did not reveal any residual tumor. Chronic inflammation with fibrosis and focal granulomatous inflammation were noted (common reactions to chemotherapy). However, diffuse mast cell infiltration of the bladder wall is unusual.
Mastocyte accumulation in the bladder mucosa and detrusor muscle can be seen in multiple conditions, including normal aging, interstitial cystitis, mechanical trauma, and parasitic or bacterial infections. The clinical symptoms of pain, dysuria, and frequency are similar to those observed in interstitial cystitis/ bladder pain syndrome, which suggested the possibility of interstitial cystitis in the present patient's scenario. The diagnosis of interstitial cystitis is predominantly a clinical diagnosis, and no definite pathologic criteria have been established. The primary mechanisms that trigger interstitial cystitis have yet to be elucidated. However, the role of activated mast cells, especially those associated with nerve fibers in the development of interstitial cystitis symptoms, has been suggested by multiple studies. [10] [11] [12] [13] [14] Animal models also showed that mast cells play a crucial role in the development of pain in cystitis through the release of histamine and tumor necrosis factor. 14, 15 Diffuse mast cell infiltration of the detrusor muscle along with perineural mast cell accumulation ( Figure 7 ) could explain the aggravation of this patient's pain after she received 2 cycles of chemotherapy. Furthermore, the patient had exposure to intravesical mitomycin 1 month before the start of neoadjuvant chemotherapy. It is well-known that intravesical mitomycin can cause chemical cystitis, and case reports have been published of eosinophilic cystitis after mitomycin-C intravesical instillation. 16 However, most of these cases occurred as a delayed hypersensitivity reaction after multiple intravesical treatments for superficial bladder tumors, and none of them had diffuse mast cell infiltration. This supports the idea that chemotherapy could be one of the factors causing activation and degranulation of mast cells, resulting in a clinical picture similar to interstitial cystitis.
Conclusions
This type of overwhelming inflammatory response may be a biomarker of complete response to chemotherapy. This phenomenon may be studied and thus developed as a strategy to avoid cystectomy. Moreover, this case also underscores the fact that radiographic appearance does not always correlate with the histopathologic changes in the tumor as a response to systemic chemotherapy. hematoxylin-eosin, original magnification x200); higher magnification of the mast cells (right inset; original magnification x400) and perineural mast cell involvement (left inset; original magnification x400). 
